- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
- Interventions
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810, Placebo
- Diagnostic Test · Behavioral · Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- Lakeland, Florida • Maitland, Florida • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Impulsive Aggression
- Interventions
- Not listed
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SPN-810
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Schizophrenia
- Interventions
- Risperidone, divalproex
- Drug
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Orangeburg, New York
- Conditions
- Schizophrenia, Impulsive Behavior
- Interventions
- Nicotine Patch, 7 Mg/24 Hr, Placebo patch
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Impulsive Aggression, Posttraumatic Stress Disorder
- Interventions
- Phenytoin, Cognitive Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Michael E. DeBakey VA Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Impulsive Aggression Comorbid With ADHD
- Interventions
- SPN-810, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 27
- States / cities
- Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more
- Conditions
- Cardiovascular Diseases, Mood Disorders, Inflammation
- Interventions
- Fish Oil, Soybean Oil (Placebo)
- Dietary Supplement
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 30 Years to 55 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Impulsive Aggression Comorbid With ADHD in Children
- Interventions
- Molindone
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Los Angeles, California • Santa Ana, California + 25 more
- Conditions
- Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Depressive Symptoms, Anxiety, Substance Use, Aggression, Coping Skills, Impulsive Behavior, Housing Problems, Recidivism, Stress, Occupational Stress, Psychological Distress
- Interventions
- Resiliency in Stressful Experiences (RISE) Program
- Behavioral
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Borderline Personality Disorder
- Interventions
- guanfacine (Tenex)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia, Cognitive Deficits, Impulsive Aggression, Emotion, Impulsivity
- Interventions
- Cognitive Remediation (CRT), CRT+ Social Cognition Training
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • White Plains, New York
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SPN-810 (18 mg), SPN-810 (36 mg), Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 28
- States / cities
- Rogers, Arkansas • Culver City, California • Glendale, California + 22 more
- Conditions
- Borderline Personality Disorder
- Interventions
- Dialectical Behavioral Therapy, Escitalopram
- Behavioral · Drug
- Lead sponsor
- Bronx VA Medical Center
- Federal
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- SPN-810, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
- Conditions
- Schizophrenia Disorder, Schizoaffecitve Disorder, Aggression
- Interventions
- Mindfulness-Based Virtual Reality Intervention
- Other
- Lead sponsor
- Manhattan Psychiatric Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • White Plains, New York
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SPN-810 (18 mg), SPN-810 (36 mg), Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Imperial, California + 29 more